Tiedemann Advisors LLC Acquires 656 Shares of Edwards Lifesciences Corp (NYSE:EW)

Share on StockTwits

Tiedemann Advisors LLC raised its holdings in Edwards Lifesciences Corp (NYSE:EW) by 48.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,022 shares of the medical research company’s stock after buying an additional 656 shares during the period. Tiedemann Advisors LLC’s holdings in Edwards Lifesciences were worth $444,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in EW. Pegasus Asset Management Inc. lifted its position in shares of Edwards Lifesciences by 0.3% during the third quarter. Pegasus Asset Management Inc. now owns 14,154 shares of the medical research company’s stock valued at $3,113,000 after purchasing an additional 43 shares in the last quarter. Stephens Inc. AR raised its position in Edwards Lifesciences by 0.6% in the third quarter. Stephens Inc. AR now owns 7,482 shares of the medical research company’s stock worth $1,645,000 after acquiring an additional 45 shares during the period. Ledyard National Bank raised its position in Edwards Lifesciences by 0.5% in the second quarter. Ledyard National Bank now owns 9,178 shares of the medical research company’s stock worth $1,696,000 after acquiring an additional 50 shares during the period. Municipal Employees Retirement System of Michigan raised its position in Edwards Lifesciences by 1.8% in the second quarter. Municipal Employees Retirement System of Michigan now owns 2,880 shares of the medical research company’s stock worth $532,000 after acquiring an additional 50 shares during the period. Finally, Optimum Investment Advisors raised its position in Edwards Lifesciences by 11.1% in the third quarter. Optimum Investment Advisors now owns 500 shares of the medical research company’s stock worth $110,000 after acquiring an additional 50 shares during the period. 80.53% of the stock is currently owned by hedge funds and other institutional investors.

Shares of EW traded up $4.03 during trading hours on Friday, hitting $244.59. The company’s stock had a trading volume of 940,502 shares, compared to its average volume of 1,179,429. The company has a market cap of $50.80 billion, a price-to-earnings ratio of 52.04, a PEG ratio of 2.90 and a beta of 0.82. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.53 and a quick ratio of 2.74. The business has a 50 day simple moving average of $228.71 and a two-hundred day simple moving average of $204.82. Edwards Lifesciences Corp has a 52-week low of $139.64 and a 52-week high of $242.60.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.19. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The company’s revenue was up 20.7% on a year-over-year basis. During the same quarter last year, the company earned $1.07 earnings per share. Research analysts predict that Edwards Lifesciences Corp will post 5.6 earnings per share for the current year.

In related news, CFO Scott B. Ullem sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $213.44, for a total transaction of $1,600,800.00. Following the completion of the transaction, the chief financial officer now owns 21,064 shares of the company’s stock, valued at $4,495,900.16. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 22,850 shares of the business’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $216.70, for a total transaction of $4,951,595.00. Following the transaction, the chief executive officer now directly owns 95,770 shares of the company’s stock, valued at approximately $20,753,359. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 153,231 shares of company stock valued at $34,483,374. 1.63% of the stock is owned by corporate insiders.

Several brokerages have commented on EW. UBS Group lifted their price objective on shares of Edwards Lifesciences from $205.00 to $230.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 16th. BTIG Research reaffirmed a “hold” rating on shares of Edwards Lifesciences in a research report on Thursday, July 25th. Bank of America lifted their price objective on shares of Edwards Lifesciences from $225.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. ValuEngine lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Credit Suisse Group lifted their price objective on shares of Edwards Lifesciences from $226.00 to $261.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating to the company. Edwards Lifesciences has a consensus rating of “Buy” and an average price target of $237.89.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

See Also: How Buying a Call Option Works

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Expect ENDRA Life Sciences Inc  to Post -$0.24 EPS
Zacks: Analysts Expect ENDRA Life Sciences Inc to Post -$0.24 EPS
Hannon Armstrong Sustnbl Infrstr Cap Inc  Receives $29.50 Consensus PT from Analysts
Hannon Armstrong Sustnbl Infrstr Cap Inc Receives $29.50 Consensus PT from Analysts
EXMR  Price Up 9,902.1% This Week
EXMR Price Up 9,902.1% This Week
NANJCOIN  Market Capitalization Achieves $282,088.00
NANJCOIN Market Capitalization Achieves $282,088.00
Data Transaction Token Market Cap Hits $185,139.00
Data Transaction Token Market Cap Hits $185,139.00
Manchester United  Given Daily News Impact Rating of 1.00
Manchester United Given Daily News Impact Rating of 1.00


© 2006-2019 Ticker Report